Actively Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY4005130 in Adults With Non-Segmental Vitiligo
Led by Eli Lilly and Company · Updated on 2026-06-04
60
Participants Needed
35
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the tolerability and side effects of LY4005130 in adults with non-segmental vitiligo (NSV). This phase 2 study compares LY4005130 to a placebo and aims to understand how the study drug affects the body and how the body processes it. The study is sponsored by Eli Lilly and Company and focuses on participants with NSV involving specific body surface areas. Participants will receive either LY4005130 or a placebo through intravenous (IV) infusions. The study includes a 24-week treatment period with randomized, double-blind administration of the study drug or placebo. The treatment effects will be compared primarily by measuring changes in facial vitiligo area, with additional assessments of total vitiligo area and biological markers from skin biopsies and blood samples. The study lasts about 48 weeks including screening. During this time, participants will undergo blood tests to monitor drug processing and effects, skin biopsies for gene expression analysis, and other evaluations of vitiligo severity using scoring indexes. Safety and response will be closely monitored, and the main outcome measured is the percentage of participants achieving significant improvement in facial vitiligo area at week 24.
CONDITIONS
Brief Title
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- Clinical diagnosis of non-segmental vitiligo for at least 3 months
- Body surface area involvement between 4% and 60%, excluding palms and soles
- At least 0.5% body surface area involvement on the face
- Facial Vitiligo Area Scoring Index (F-VASI) score of 0.5 or higher and Total Vitiligo Area Scoring Index (T-VASI) score of 3 or higher
- Disease that is either active or stable at screening and baseline
You will not qualify if you...
- Having other types of vitiligo not considered active or stable
- Active pigmentation disorders other than vitiligo
- Active inflammatory skin diseases or skin conditions affecting vitiligo assessment
- Superficial skin infection within 2 weeks before baseline (rescreening allowed after resolution)
- History of chronic alcohol abuse, intravenous drug abuse, or illicit drug abuse within 1 year prior to screening
- History or presence of serious or unstable medical conditions that pose unacceptable risk or interfere with study data interpretation
- Previous use of any JAK inhibitor therapy, systemic or topical (e.g., ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 weeks
Participants receive LY4005130 or placebo administered intravenously.
Trial Site Locations
Total: 35 locations
1
Medical Dermatology Specialists
Phoenix, Arizona, United States, 85006
Actively Recruiting
2
Saguaro Dermatology - Phoenix
Phoenix, Arizona, United States, 85008
Not Yet Recruiting
3
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States, 94538
Actively Recruiting
4
Northridge Clinical Trials
Northridge, California, United States, 91325
Actively Recruiting
5
Cura Clinical Research - Oxnard
Oxnard, California, United States, 93030
Actively Recruiting
6
Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
Santa Clarita, California, United States, 91355
Not Yet Recruiting
7
Health Clinical Research, LLC
Miami, Florida, United States, 33189
Actively Recruiting
8
K2 Medical Research - Tampa
Tampa, Florida, United States, 33634
Actively Recruiting
9
Advanced Medical Research, PC.
Sandy Springs, Georgia, United States, 30328
Actively Recruiting
10
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States, 46250
Actively Recruiting
11
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
12
Revival Research Institute, LLC
Troy, Michigan, United States, 48084
Actively Recruiting
13
Stracskin
Portsmouth, New Hampshire, United States, 03801
Actively Recruiting
14
Equity Medical
The Bronx, New York, United States, 10455
Actively Recruiting
15
Accurate Clinical Research, Inc
Humble, Texas, United States, 77346
Actively Recruiting
16
Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
San Antonio, Texas, United States, 78235
Actively Recruiting
17
Jordan Valley Dermatology & Research Center
South Jordan, Utah, United States, 84095
Actively Recruiting
18
Clinical Research Partners, LLC
Richmond, Virginia, United States, 23226
Actively Recruiting
19
Anima Diepenbeek
Diepenbeek, Belgium, 3590
Not Yet Recruiting
20
UZ Gent
Ghent, Belgium, 9000
Not Yet Recruiting
21
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, Belgium, 4000
Not Yet Recruiting
22
INTERMED Groupe Sante
Chicoutimi, Canada, G7H 7Y8
Actively Recruiting
23
DermEffects
London, Canada, N6H 5L5
Not Yet Recruiting
24
Dar Clinical Research - Ottawa - Hunt Club Road
Ottawa, Canada, K1V 1C1
Not Yet Recruiting
25
The Centre for Dermatology
Richmond Hill, Canada, L4B 1A5
Not Yet Recruiting
26
Research Toronto
Toronto, Canada, M4W 2N4
Not Yet Recruiting
27
SIMa Recherche
Verdun, Canada, H4G 2L8
Not Yet Recruiting
28
Peking University People's Hospital
Beijing, China, 100034
Not Yet Recruiting
29
Hangzhou Third People's Hospital
Hangzhou, China, 310009
Not Yet Recruiting
30
Shanghai Skin Disease Hospital
Shanghai, China, 200071
Not Yet Recruiting
31
The University of Hong Kong-Shenzhen Hospital
Shenzhen, China, 518053
Not Yet Recruiting
32
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Poland, 80-546
Not Yet Recruiting
33
Diamond Clinic
Krakow, Poland, 31-559
Not Yet Recruiting
34
Dermedic Jacek Zdybski
Ostrowiec Świętokrzyski, Poland, 27-400
Not Yet Recruiting
35
Centrum Medyczne Ginemedica
Wroclaw, Poland, 50-414
Not Yet Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here